Clinical Scorecard: Evaluation of SPIO-Enhanced MRI in Distinguishing Metastatic Lymph Nodes from Reactive Hyperplasia in Breast Cancer: Diagnostic Efficacy and Correlation with VEGF-C Levels

At a Glance

Key Highlights

• SPIO-enhanced MRI achieved 84% overall diagnostic accuracy in distinguishing lymph node types.
• Mean Percentage of Signal Intensity Loss (PSIL) was significantly different between metastatic (11.6%) and reactive nodes (64.7%).
• High VEGF-C expression was found more frequently in metastatic nodes (85.1%) compared to reactive nodes (12.3%).
• The study supports the use of SPIO-enhanced MRI as a non-invasive alternative for lymph node assessment.

Guideline-Based Recommendations

Diagnosis

• Utilize SPIO-enhanced MRI for non-invasive assessment of lymph node status in breast cancer.

Management

• Consider SPIO-enhanced MRI findings in treatment planning and staging of breast cancer.

Monitoring & Follow-up

• Monitor VEGF-C levels as a potential biomarker associated with lymph node metastasis.

Risks

• Be aware of potential complications from extensive lymph node dissection, including lymphedema and nerve injury.

Patient & Prescribing Data

60 female patients aged 28-68 with confirmed breast cancer.

Patients had no prior chemotherapy, radiotherapy, or endocrine therapy before MRI evaluation.

Clinical Best Practices

• Incorporate SPIO-enhanced MRI into standard imaging protocols for lymph node evaluation in breast cancer.
• Evaluate PSIL in conjunction with histopathological findings for accurate diagnosis.

References

• SPIO-enhanced MRI Study